Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Deferred Taxes (2020 - 2024)

Historic Deferred Taxes for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Q4 2024 value amounting to $11000.0.

  • Maravai Lifesciences Holdings' Deferred Taxes fell 9999.86% to $11000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $11000.0, marking a year-over-year decrease of 9999.85%. This contributed to the annual value of $11000.0 for FY2024, which is 9999.85% down from last year.
  • According to the latest figures from Q4 2024, Maravai Lifesciences Holdings' Deferred Taxes is $11000.0, which was down 9999.86% from $764.8 million recorded in Q4 2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Deferred Taxes ranged from a high of $764.8 million in Q4 2023 and a low of -$5.5 million during Q3 2023
  • Its 5-year average for Deferred Taxes is $52.4 million, with a median of $6.7 million in 2021.
  • In the last 5 years, Maravai Lifesciences Holdings' Deferred Taxes soared by 112280000.0% in 2021 and then crashed by 15990.9% in 2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Deferred Taxes (Quarter) stood at -$4.2 million in 2020, then surged by 516.95% to $17.5 million in 2021, then plummeted by 59.86% to $7.0 million in 2022, then skyrocketed by 10807.86% to $764.8 million in 2023, then plummeted by 100.0% to $11000.0 in 2024.
  • Its Deferred Taxes was $11000.0 in Q4 2024, compared to $764.8 million in Q4 2023 and -$5.5 million in Q3 2023.